City Therapeutics, Inc. (CTY)
NASDAQ: CTY · Real-Time Price · USD
22.40
+4.40 (24.44%)
At close: Oct 16, 2026, 4:00 PM EDT
22.15
-0.25 (-1.12%)
After-hours: Oct 16, 2026, 7:58 PM EDT

City Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Revenue
14.3413.562.78
Revenue Growth
-388.19%-
Gross Profit
-66.02-44.86-22.9
Operating Income
-84.46-59.92-29.09
Net Income
-87.67-58.51-27.84
Earnings Per Share
-15.72-12.46-8.18
EPS Growth
---

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Cash & Investments
169.61112.79126.9
Total Debt
57.0467.2822.3
Net Cash (Debt)
112.5745.51104.6
Net Cash Growth
--56.49%-
Net Cash Per Share
20.199.6930.73

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Operating Cash Flow
-77.67-41.61-20.39
Capital Expenditures
-3.08-2.41-3.54
Free Cash Flow
-80.75-44.02-23.93
Free Cash Flow Growth
---

Margins

Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Operating Margin
-588.90%-441.84%-1047.16%
Pretax Margin
-611.25%-431.39%-1002.02%
Profit Margin
-611.25%-431.39%-1002.02%
FCF Margin
-563.00%-324.55%-861.34%